Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy Pharmaceutical Investing
Johnson & Johnson Names Darius Adamczyk, Chairman and Chief Executive Officer of Honeywell, to its Board of Directors Pharmaceutical Investing
Pfizer and OPKO's Once-Weekly NGENLA Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency Life Science Investing
European Medicines Agency Approves Pfizer's 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults Life Science Investing
Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion Pharmaceutical Investing
BetterLife Lead Drug Promotes Structural Neural Plasticity in Preclinical Model Pharmaceutical Investing
AbbVie and the University of Toronto Establish Endowed Chair in Ethnodermatology Pharmaceutical Investing
Opdivo® in Combination with CABOMETYX® Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Pharmaceutical Investing
LYNPARZA® Plus Abiraterone Reduced Risk of Disease Progression or Death by 34% Versus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer, Regardless of Biomarker Status Life Science Investing
